i) SARS-CoV-2 PCR positive COVID-19 patient ii) Heart failure iii) Sleep apnea syndrome iv) Asthma v) Chronic obstructive pulmonary disease vi) Intestinal pneumonia vii) Pulmonary mycobacterium avium complex disease viii) Pediatric inguinal hernia ix) Congenital cystic disease of lung x) Pediatric metastatic lung tumors xi) Pneumonia
Conditions
Interventions
None listed
Sponsors
Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
National Institute of Advanced Industrial Science and Technology (AIST), Keio University, Tohoku University, Nagoya University, CureApp Inc, Cosmic M.E. Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i) SARS-CoV-2 PCR positive COVID-19 patient ii) Heart failure iii) Sleep apnea syndrome iv) Asthma v) Chronic obstructive pulmonary disease vi) Intestinal pneumonia vii) Pulmonary mycobacterium avium complex disease viii) Pediatric inguinal hernia ix) Congenital cystic disease of lung x) Pediatric metastatic lung tumors xi) Pneumonia
Exclusion criteria
Exclusion criteria: 1) Cannot use a developed medical device 2) Cannot obtain a written informed consent because of severe medical conditions (e.g. intubated) 3) Principle investigators considered inappropriate for eligibility 4) Pneumonia patients with A-DROP score equal or more than 3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulse rate and SpO2 | — |
Countries
Japan
Contacts
Public ContactAkihiro Nomura
Kanazawa University Innovative Clinical Research Center / Department of Cardiovascular Medicine
Outcome results
None listed